Ken Griffin Abb Vie Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $178 Million - $217 Million	1,088,300 Added 139.56%	1,868,100 $369 Million
Q2 2024 Aug 14, 2024	SELL	$154.79 - $180.76 $117 Million - $136 Million	-753,000 Reduced 49.13%	779,800 $134 Million
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $63.6 Million - $72.4 Million	397,800 Added 35.05%	1,532,800 $279 Million
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $47 Million - $53 Million	-341,800 Reduced 23.14%	1,135,000 $176 Million
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $83.4 Million - $96.5 Million	-624,100 Reduced 29.71%	1,476,800 $220 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $16.4 Million - $20.4 Million	-123,700 Reduced 5.56%	2,100,900 $283 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $38.4 Million - $44.2 Million	-265,700 Reduced 10.67%	2,224,600 $355 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $43.3 Million - $51.9 Million	313,000 Added 14.38%	2,490,300 $403 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $45 Million - $51.6 Million	-335,100 Reduced 13.34%	2,177,300 $292 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.